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Abstract: 
Objective: 
To investigate whether comparing observed with expected p-value distributions for baseline 
continuous variables in randomised controlled trials (RCTs) might be limited by 
randomisation methods, normality and correlation of variables, or calculation of p-values 
from rounded summary statistics. 
 
Study Design and Setting: 
We assessed how each factor affects differences from expected for p-value distributions and 
area under the curve of the cumulative distribution function (AUC-CDF) of baseline p-values 
in 13 RCTs and in simulations.  
 
Results: 
The p-value distributions and AUC-CDF for variables with possible non-normal distribution 
and in simulations using eight different randomisation methods were consistent with the 
theoretical uniform distribution and AUC-CDF respectively, although stratification and 
minimisation produced smaller-than-expected proportions of p-values <0.10. 77% of 3813 
pairwise correlations between baseline variables in the 13 individual RCTs were between -0.2 
and 0.2. P-value distribution and AUC-CDF remained consistent with the uniform 
distribution in simulations with incrementally increasing correlation strength. The p-value 
distributions calculated from rounded summary statistics were not uniform, but expected 
distributions could be empirically generated.  
 
Conclusions: 
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Randomisation methods, non-normality and strength of correlation of baseline variables did 
not have important effects on baseline p-value distribution or AUC-CDF, but baseline p-
values calculated from rounded summary statistics are non-uniformly distributed.  
 
Key words: Statistical Methods, Research Integrity, P-values, Correlation, Randomisation, 
Rounding 
 
Running title: Factors affecting baseline p-value distribution 
 
What is new? 
• Non-normal distribution of baseline continuous variables, eight common 
randomisation methods, and correlation of baseline variables did not have important 
effects on baseline p-value distribution 
• However, the distribution of p-values calculated from rounded summary statistics is 
not uniform, although the expected distribution can be empirically generated. 
• Concerns that correlation and non-normality of baseline variables or randomisation 
methods would impact on baseline p-value distribution in genuine RCTs do not 
appear to be justified. 
• Distribution of baseline p-values calculated from rounded summary statistics should 
be compared to empirically generated distributions not the uniform distribution. 
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1.1 Introduction 
The distribution of baseline variables in groups of randomised controlled trials (RCTs) has 
been used in assessment of research integrity and potential research misconduct, when there 
have been prior concerns about the research [1-4]. Previously, we assessed the distribution of 
p-values from comparisons between baseline variables in a group of RCTs about which 
concerns had been raised [3]. To date, at least some of these RCTs were determined to be 
fraudulent [5]. In theory, because participants in a RCT are randomly allocated to study 
groups, the expected distribution of p-values from comparisons between randomised groups 
for independent baseline continuous variables (baseline p-values) is uniform. In an 
accompanying paper, we assessed the distribution of baseline p-values in a dataset of 
individual patient data from 13 placebo-controlled RCTs carried out by our research group 
over the past 20 years [6]. In this dataset, the average distribution of baseline p-values from 
comparisons of continuous variables was uniform, with only small differences from the 
expected distributions. However, it has been suggested that baseline p-values may not be 
uniform when techniques other than simple randomisation are used [7]. In addition, concerns 
have been raised that non-normal, or fixed and/or highly correlated baseline variables may 
lead to non-uniformly distributed baseline p-values [7-9].  Here, we extend our previous 
analyses by exploring the impact of different randomisation methods, non-normal distribution 
of variables and increasingly strong correlation between variables on the distribution of 
baseline p-values and the area under the curve (AUC) of the cumulative distribution function 
(CDF) of these p-values from continuous variables in the dataset of our trials and in 
simulations. 
 
Many groups and journals recommend against reporting of p-values from between-group 
comparisons of baseline variables in manuscripts, even though it remains a common practice 
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[10]. When baseline p-values are not reported, they can be calculated from the reported 
summary statistics (mean, standard deviation, n) using parametric tests. As these summary 
statistics are invariably rounded, the calculated p-values are likely to differ from those 
calculated from raw data. We also explored what effect rounding has on the distribution of 
baseline p-values and the AUC-CDF. 
 
1.2 Methods 
1.2.1 Datasets of RCTs: 
We pooled anonymised individual patient data from 13 single-centre, placebo-controlled 
RCTs [11-23] carried out by our group, as previously described [6]. Table 1 shows selected 
features of the 13 RCTs. All trials were carried out in older people and studied osteoporosis 
treatment and prevention. Four were carried out in specific conditions (HIV, sarcoidosis, 
diabetes, osteoporosis), three in healthy women with osteopenia, and the other six in healthy 
individuals. Randomisation was by a minimisation algorithm for 1 RCT, using stratification 
for 1 RCT, and using variable block sizes for 11 RCTs. For these analyses, the pooled dataset 
was restricted to 30 commonly presented baseline continuous variables (Table 2) to represent 
the typical “real world” presentation of baseline data. The number of baseline variables in 
each trial ranged from 18 to 28, and the entire dataset contained 319 variables from the 13 
RCTs. 
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Table 1: Design and baseline characteristics and variables in 13 randomised controlled trials 
in the individual patient dataset. 
 
Study 
 
N Mean 
Age 
(y) 
Population Design Agent Baseline 
variables 
(N) 
Randomisation 
method 
Reid 1993 [11] 135 58 Older women 2-arm Calcium 22 Variable blocks 
Reid 2000 [12] 185 63 Older women 2-arm Hydrochlorothiazide 26 Stratification 
(2 variables) 
block size 4 
Reid 2005 [13] 41 63 Older women 2-arm Propranolol 18 Variable blocks 
Reid 2006 [14] 1471 74 Older women 2-arm Calcium 19 Minimisation 
(3 variables) 
Bolland 2007 [15] 43 49 HIV-infected men 2-arm Zoledronate 27 Variable blocks 
Grey 2007 [16] 50 67 Older women 2-arm Rosiglitazone 28 Variable blocks 
Reid 2007 [17] 80 65 Women, osteoporosis 2-arm Fluoride 26 Variable blocks 
Reid 2008 [18] 323 56 Older men 3-arm Calcium 25 Variable blocks 
Grey 2009 [19] 50 64 Women, osteopenia 2-arm Zoledronate 26 Variable blocks 
Grey 2012 [20] 180 65 Women, osteopenia 4-arm Zoledronate 25 Variable blocks 
Bolland 2013 [21] 27 57 Sarcoidosis 2-arm Vitamin D 28 Variable blocks 
Grey 2013 [22] 180 69 Women, osteopenia 4-arm Fluoride 25 Variable blocks 
Grey 2014 [23] 86 64 Diabetes 2-arm Pioglitazone 24 Variable blocks 
 
 
1.2.2 Calculation of baseline p-values 
We compared the means of the baseline variables between randomised groups with a t-test or 
one-way ANOVA using individual, raw, unrounded data for each RCT in the primary 
analyses. We repeated these comparisons using non-parametric Wilcoxon or Kruskal-Wallis 
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tests. The distribution of baseline p-values by decile was compared to the expected uniform 
distribution using a one-way chi-square test. We also calculated the AUC of the CDF of the 
baseline p-values, and compared the AUC to that of the uniform distribution (0.50) [6]. To 
estimate the likely random variation in p-value distribution, we undertook 100 simulations in 
which each trial was re-randomised using the original randomisation method (Table 1) and 
compared the baseline variables with a t-test or one-way ANOVA for each re-randomisation. 
 
1.2.3 Effects of randomisation methods 
We generated a dataset with 100 simulated randomisations of the 13 RCTs using eight 
different randomisation methods. Separate randomisations were carried out for each 
simulation and each RCT. First, a uniformly distributed random number was generated in 
each simulation for each participant in each RCT. Then the different methods of 
randomisation were used to form simulated treatment groups. 1. Simple randomisation: 
groups were formed based on appropriate thresholds (0.5 for two-arm studies, 0.333 and 
0.667 for three-arm studies, and 0.25, 0.5, and 0.75 for four arm studies). 2. Randomisation in 
one block per group: groups were formed based on the median, tertile or quartile of random 
numbers. 3. Fixed block size: block sizes of 4 for two-arm and four-arm studies, and 3 for 
three-arm studies were used. 4. Variable block size: block sizes between 4 and 20, or 3 and 
18 respectively were used. 5. Stratified one block: participants were stratified into 8 groups 
by the median value for age, weight and lumbar spine bone density, and then groups were 
formed based on the median, tertile or quartile of random numbers for each stratum. 6. 
Stratified fixed block: block sizes of 4 for two-arm and four-arm studies, and 3 for three-arm 
studies were used for each stratum. 7. Minimisation: treatments were assigned using a 
minimisation algorithm that aimed to balance treatment groups for age, weight and lumbar 
spine bone density (using median value for each study as threshold). 8. Weighted 
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minimisation: there was an 80% chance of treatment being assigned using minimisation and a 
20% chance of treatment being assigned using simple randomisation. The p-values for age, 
weight, and lumbar spine bone density were not included in analyses of the distribution of 
baseline p-values for the stratified or minimisation analyses. 
 
1.2.4 Effect of normality of distribution 
We assessed whether the baseline continuous variables in the pooled original dataset were 
normally distributed using the Shapiro-Wilk test and identified any variables with P<0.05 and 
P<0.001 respectively, which suggested a non-normal distribution. We then restricted the 
analyses of baseline p-values by decile to these variables with possible non-normal 
distribution.  
 
We generated a dataset of 100 simulations of normally distributed baseline variables (the 
‘simulated normal dataset’) in which each simulated observation for an individual was 
generated using a normally distributed random number based on the mean and standard 
deviation for each variable from each of the 13 RCTs and individuals were randomised in a 
single block per treatment group to ensure group numbers were similar. Analyses were 
repeated in this dataset, in which there were few variables that were highly non-normally 
distributed.  
 
1.2.5 Effect of correlation of baseline variables 
Spearman correlations were calculated for baseline variables in the RCTs and Pearson 
correlations for the simulated normal dataset.  
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To assess the effect of increasing strength of correlation of variables on the distribution of 
baseline p-values, we generated a dataset of 100 simulations of five normally distributed 
variables (age, height, weight, lumbar spine bone density and serum creatinine) based on the 
mean, standard deviation, and covariance matrix of the variable in each of the 13 RCTs using 
the IML procedure in SAS. We then increased each pairwise correlation between variables 
away from 0 by 0.1, converted the correlation matrix to a covariance matrix and repeated the 
simulation. If correlation matrices were invalid, the nearest valid correlation matrix was 
estimated and used [24, 25]. We repeated these analyses using all baseline variables from 
each study. 
 
We also assessed the impact of clustering of correlated variables on baseline p-values. By 
chance, there may be a large difference in a variable between randomised groups. If this 
variable is highly correlated with other variables, it might be expected that those variables 
may also differ between groups. The converse argument would apply for closely matched 
variables. We therefore restricted our analyses to simulations with P<0.10 or P>0.90 for age 
from the comparison of randomised groups in the simulated datasets with increasing 
correlation between five variables based on the correlation matrices of the RCTs. We then 
assessed the distribution of baseline p-values for the other four variables.  
 
1.2.6 P-values calculated from rounded summary statistics 
To assess the effect of rounding of summary statistics on the distribution of p-values, we 
calculated the mean and standard deviation for each variable for each of the 13 RCTs, 
rounded these summary data, and calculated the p-values from them using a t-test or one way 
ANOVA. We used two levels of rounding: firstly, typical rounding that might be presented in 
a manuscript, and secondly an extreme level of rounding (Table 2). We performed these 
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analyses in the dataset of RCTs with 100 simulated randomisations (with individuals 
randomised in one block per treatment group to ensure group numbers were similar), and in 
the simulated normal dataset.  
 
 
Table 2: 30 variables commonly presented in baseline trial data 
 
Category Variable Mean (SD) Common 
rounding 
Extreme 
rounding 
Clinical 
characteristics 
Age (y) 
68.3 (9.6) 
0.1 (0.1) 1 (1) 
 Age at menopause (y) 49 (5) 1 (1) 1 (1) 
 Height (cm) 162.3 (8.3) 0.1 (0.1) 1 (1) 
 Weight (kg) 69.5 (13) 0.1 (0.1) 1 (1) 
Full blood count Haemoglobin (g/L) 136 (10) 1 (1) 1 (1) 
 White blood cell count (cells/L) 5.7 (1.6) 0.1 (0.1) 1 (1) 
Basic biochemistry Albumin (g/L) 43 (2.6) 1 (0.1) 1 (1) 
 Creatinine (umol/L) 84 (15) 1 (1) 1 (1) 
 Glucose (mmol/L) 5.1 (0.7) 0.1 (0.1) 0.1 (0.1) 
 Potassium (mmol/L) 4.4 (0.4) 0.1 (0.1) 0.1 (0.1) 
 Sodium (mmol/L) 141 (2.2) 1 (0.1) 1 (1) 
Liver function Alkaline phosphatase (U/L) 80 (22) 1 (1) 1 (1) 
 Aspartate transaminase (U/L) 23 (6.4) 1 (0.1) 1 (1) 
 Bilirubin (umol/L) 12 (6.1) 1 (0.1) 1 (1) 
 Gamma-glutamyl transferase (U/L) 23 (18) 1 (1) 1 (1) 
Serum calcium  Calcium (mmol/L) 2.33 (0.09) 0.01 (0.01) 0.01 (0.01) 
and bone parameters Phosphate (mmol/L) 1.15 (0.15) 0.01 (0.01) 0.1 (0.1) 
 25-hydroxyvitamin D (nmol/L) 63 (26) 1 (1) 1 (1) 
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 1,25 dihydroxyvitamin D (pmol/L) 105 (32) 1 (1) 1 (1) 
 β-C-terminal telopeptide of type I collagen (ug/L) 0.41 (0.20) 0.01 (0.01) 0.01 (0.01) 
 Procollagen type-I N-terminal propeptide (ug/L) 48 (20) 1 (1) 1 (1) 
 Parathyroid hormone (pmol/L) 3.6 (1.5) 0.1 (0.1) 0.1 (0.1) 
 Urine calcium (mmol/L) 2.27 (1.91) 0.01 (0.01) 0.1 (0.1) 
 Dietary calcium intake (mg/d) 879 (430) 1 (1) 1 (1) 
Dual energy X-ray  Lumbar spine (g/cm2) 1.09 (0.19) 0.01 (0.01) 0.01 (0.01) 
absorptiometry Total hip (g/cm2) 0.91 (0.15) 0.01 (0.01) 0.01 (0.01) 
 Femoral neck (g/cm2) 0.86 (0.14) 0.01 (0.01) 0.01 (0.01) 
 Total body (g/cm2) 1.08 (0.12) 0.01 (0.01) 0.01 (0.01) 
 Lean mass (kg) 39.6 (9.3) 0.1 (0.1) 1 (1) 
 Fat mass (kg) 25.7 (9.5) 0.1 (0.1) 1 (1) 
 
The mean and standard deviation (SD) are the summary data from all 13 randomised 
controlled trials. The rounding columns show two different levels used to round summary 
statistics from which baseline p-values were calculated. 
 
 
 
When rounded summary means are identical, the p-value calculated from summary statistics 
is 1. To determine whether simulating p-values might overcome this issue, we performed 
1000 simulations for each variable in the dataset of 100 simulated randomisations (with 
individuals randomised in one block per treatment group) and in the simulated normal 
dataset. 1000 simulated means and standard deviations for each rounded mean and standard 
deviation for each variable in each treatment group for each of the 13 RCTs were calculated 
using uniformly distributed random numbers that lay within the minimum and maximum 
rounding of the variable. For example, for a mean of 30, 1000 values uniformly distributed 
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between 29.5 and 30.5 were generated. Likewise, for a standard deviation of 0.15, 1000 
values between 0.145 and 0.155 were generated. The p-value for the difference between 
groups for each simulation was then calculated from the unrounded simulated means and 
standard deviations, and the mean of the 1000 p-values from the simulations used in place of 
the p-value calculated from the summary statistics.  
 
1.2.7 Analyses 
All analyses were performed with SAS (SAS Institute, Cary, NC version 9.4). The 
distributions of p-values grouped by decile were compared to the expected uniform 
distribution using a one-way chi-square test. The AUC for the CDF of p-values was 
calculated using the trapezoidal method. 95% confidence intervals (CI) for the AUC for the 
319 baseline p-values were calculated from a dataset of 100 re-randomisations using the 
original trial randomisation method [6]; for other analyses they were calculated from the 2.5 
and 97.5 centiles of the AUCs of the CDF from analyses involving multiple simulations, or 
from bootstrap resampling (n=500, sampling with replacement) for analyses without multiple 
simulations. 
 
1.3 Results: 
1.3.1 Effect of randomisation method: 
The distribution of p-values from the comparison of the 319 baseline variables between the 
randomised groups in the 13 placebo-controlled RCTs was approximately consistent with a 
uniform distribution (P=0.39, difference in AUC from the uniform distribution AUC -0.03, 
[95% CI -0.04, 0.04], Figure 1), although some proportions for individual deciles differed 
from the expected proportions. Figure 1 also shows that in the dataset of 100 re-
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randomisations using the original randomisation method (Table 1), the distribution of p-
values was approximately uniform.  
 
Figure 2 shows the results of 100 simulated randomisations using eight different methods. 
For simple randomisation and randomisation in blocks, the distribution of baseline p-values 
was approximately uniform (Figures 2A-2D). When stratification or minimisation was used 
(Figures 2E-2H), visually there appeared to be a smaller-than-expected proportion of p-values 
in the lowest decile, consistent with the pattern seen in Figure 1, although in all cases the 
calculated 95% confidence interval (0.05-0.12 stratified fixed blocks; 0.06-0.13 stratified one 
block; 0.05-0.11 minimisation; 0.05-0.12 weighted minimisation) included the expected 
value of 0.10. Figure 2 and Appendix Figure A.1 show that the AUC-CDF was consistent 
with the uniform AUC for all randomisation methods. 
 
1.3.2 Effect of normality of distribution: 
Of the 319 baseline variables in 13 placebo-controlled RCTs, 212 (66%) had P<0.05 and 135 
(42%) had P<0.001 from the Shapiro-Wilk test, indicating possible non-normal distribution. 
When the baseline variables were compared using non-parametric Wilcoxon or Kruskal-
Wallis tests (Figure 3A, Appendix Figure A.2A), the distribution of p-values and the AUC of 
the CDF was similar to the distribution of p-values and AUC of the CDF from the parametric 
tests (Figure 1). In the analyses of p-values from both the parametric and non-parametric 
tests, there appeared to be a smaller-than-expected proportion of p-values in the lowest 
(<0.10) decile (95% confidence interval 0.039-0.093 for parametric p-values, 0.034-0.086 for 
non-parametric p-values). We then generated a dataset of 100 simulations of normally 
distributed variables (the ‘simulated normal dataset’) based on the means and standard 
deviations for each variable from each RCT. Figure 3B and Appendix Figure A.2B show that 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Page 14 of 28 
 
the distribution of p-values from the comparison of baseline variables and the AUC-CDF in 
the simulated normal dataset is consistent with the uniform distribution.  
 
Next, we restricted the analyses from both the pooled dataset of RCTs to the non-normally 
distributed variables with P<0.05 or P<0.001 from the Shapiro-Wilk test of normality. 
Figures 3C-D and Appendix Figure A.2C-D show that the distribution of p-values and AUC-
CDFs in these restricted analyses is similar to the results for all 319 baseline variables.  
 
1.3.3 Effect of correlation of baseline variables 
We determined the correlation between baseline variables in each individual RCT. Of the 
3813 pairwise correlations in the individual RCTs, Figure 4 shows that in 49% the correlation 
statistic was between -0.1 and 0.1; in 77% the correlation was between -0.2 and 0.2; and that 
the distribution was skewed with a higher proportion of correlation statistics >0.2 (16%) than 
<-0.2 (7%). In the simulated normal dataset, Figure 4 shows that there were fewer moderately 
or highly correlated variables, the distribution of the correlations was symmetrical, in 66% 
the correlation statistic was between -0.1 and 0.1, and in 90% the correlation was 
between -0.2 and 0.2. 
 
Figures 1 and 3B show that the distribution of p-values from the comparison of baseline 
variables is approximately uniform, both in the simulated normal dataset with few moderate 
or strongly correlated baseline variables and in the RCTs which had a higher proportion of 
more correlated variables. 
 
In 100 simulations of five variables (age, height, weight, lumbar spine bone density and 
serum creatinine) based on the mean, standard deviation, and covariance matrix of the 
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variable in each of the 13 RCTs, increasing correlation between variables had little effect on 
the distribution of baseline p-values. Figure 5 and Appendix Figures A.3, A.4 show the 
distribution of correlations and AUC-CDF for each simulated level of correlation and that, 
despite the increases in correlation, the distribution of baseline p-values is uniform and the 
AUC of the CDF consistent with the uniform AUC. Appendix B shows the means, standard 
deviations, and correlation matrices from the 100 simulations for each increment of 
correlation. These analyses were repeated using all baseline variables from each study. As 
larger constants were added to each correlation, there was an increasing number of RCTs for 
which valid correlation matrices were unable to be produced. Appendix Figure A.5 shows 
that as the proportion of moderate or highly correlated variables increases, the distribution of 
p-values again remains uniform. Appendix C shows the means, standard deviations, and 
correlation matrices from the 100 simulations for each increment of correlation.  
 
To assess the impact of clustering of correlated variables on baseline p-values, we repeated 
the analyses restricted to simulations with P<0.10 or P>0.90 for age from the comparison of 
randomised groups in the simulated datasets of five increasingly correlated variables. For the 
simulations based on the actual correlation matrices of the RCTs, the distribution of p-values 
for the other four variables was approximately uniform and the AUC of the CDF consistent 
with the uniform AUC (Figure 6A, Appendix Figure A.6A). However, for the simulations 
with P<0.10 for age, increasing the correlations leads to a substantial increase of p-values 
<0.2 and a rapid increase in the difference in AUC from the uniform AUC (Figures 6B-D left 
panel, Appendix Figure A.6B-F, left panel). For the simulations with P>0.90 for age, 
increasing the correlations only leads to a clear non-uniform distribution and change in the 
AUC-CDF when the increased correlation was large (Figures 6B-6D, Appendix Figure A.6B-
F, right panel). 
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1.3.4 Baseline p-values calculated from rounded summary statistics 
In the dataset of RCTs with 100 simulated randomisations, the distribution of baseline p-
values and AUC of the CDF of these p-values calculated from rounded summary statistics is 
not consistent with the uniform distribution or AUC, with larger-than-expected proportions of 
p-values >0.9 and <0.1, and smaller-than-expected proportions between 0.5 and 0.9 (Figure 
7A, Appendix Figure A.7). These effects were more pronounced when extreme rounding was 
used (Figure 7B), and also in RCTs with two arms compared to those with three or four arms 
(Figures 7C-7F). 
 
When rounded summary means are identical, the p-value calculated from summary statistics 
is 1. This situation explains a large proportion of the excess p-values >0.9 seen in Figures 
7A-7F. To determine whether simulating p-values might produce a more uniform 
distribution, we used the mean of the 1000 p-values calculated from 1000 simulated means 
and standard deviations for each variable in each treatment group for each of the 13 RCTs. 
Figures 7G,H shows that the distribution of simulated p-values is not uniform with a smaller-
than-expected proportion of p-values >0.9. 
 
We repeated all these analyses using rounded summary statistics from the simulated normal 
dataset. Appendix Figure A.8 shows that the results from these analyses are very similar to 
those from the analyses of the dataset of RCTs with 100 simulated randomisations. 
 
1.4 Discussion 
These results show that any differences in the distribution of p-values from the comparison of 
baseline continuous variables from a group of 13 genuine RCTs from the expected uniform 
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distribution are small, and are not substantially affected by the randomisation method, the 
normality of baseline variables, or the degree of correlation between variables. Even when 
there is a high proportion of non-normally distributed variables or moderate or strongly 
correlated variables, the distribution of baseline p-values remains approximately uniform and 
the AUC of the CDF remains consistent with the uniform AUC. Stratified randomisation and 
minimisation algorithms may lead to a smaller-than-expected proportion of p-values <0.10, 
but the effect is only small. In contrast to these minor effects, calculation of p-values from 
rounded summary statistics has important effects on the distribution of baseline p-values. 
When all p-values are calculated in this way, the distribution of baseline p-values is no longer 
uniform, with a large increase in the proportion of p-values >0.9, a small increase in p-values 
<0.1, and a small decrease in p-values between 0.5 and 0.9 compared to the uniform 
distribution. The differences from the uniform distribution are greater in two arm RCTs than 
three or four arm RCTs, and greater when rounding is extreme.  
 
The distribution of baseline p-values from simulations of variables with highly positively 
skewed lognormal distributions, and simulations in which all variables had fixed or high 
levels of correlation was not uniform [8, 9]. However, these are simulations of extreme 
situations that are unlikely to be seen in all variables across a group of properly conducted 
RCTs. Carlisle reported that non-normal distribution had little effect on an analysis of 
baseline p-values, whereas highly correlated variables could potentially alter the results, but 
was unlikely to explain the results obtained from analysis of fraudulent data [26]. Taken 
together with the results of our previous work[6], the current analyses show that the 
distribution of continuous baseline p-values in a group of RCTs is approximately uniform and 
not significantly affected by the presence of non-normally distributed variables or highly 
correlated variables that occur in real-life RCTs. Stratified randomisation and minimisation 
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algorithms may lead to a smaller-than-expected proportion of p-values <0.10, but other 
randomisation methods produce uniform baseline p-values. Therefore, it seems reasonable to 
conclude that any differences in the distribution of p-values from comparison of baseline 
continuous variables in a group of valid RCTs from the uniform distribution should only be 
small. One contributing factor to this conclusion regarding correlated variables might be that 
the restrictive inclusion criteria generally used in RCTs may produce narrower distributions 
of variables, which in turn would mean highly correlated variables could be uncommon. 
 
If there is a consistently large or small between-groups difference in a baseline variable in a 
series of RCTs, the distribution of p-values no longer remains uniform in highly correlated 
datasets (Figure 6). However, this situation is unlikely to occur in practice in independent 
RCTs, because any consistent difference or similarity between variables in independent RCTs 
suggests a failure of randomisation, unless the similarity is expected as in the case of 
randomisation stratified by a variable or the use of a minimisation algorithm. 
 
Reporting baseline p-values is not a recommended practice, though it is common [10]. Our 
results show that when baseline p-values are calculated from rounded summary data, their 
distribution is no longer uniform. The most prominent difference from the uniform 
distribution is the higher-than-expected proportion of p-values >0.9, which is more common 
in two arm RCTs and when rounding is extreme. It largely arises from the situation when the 
rounded means in the randomised groups are identical and therefore the p-value from the 
between-groups comparison is 1. Using simulated p-values is not able to overcome this issue 
and produce a uniform distribution. Therefore, when baseline p-values are calculated from 
rounded summary data it is no longer appropriate to consider the expected distribution as 
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uniform. Instead, the expected distributions are shown in Figures 7 (our RCTs) and Appendix 
Figure A.7, A.8 (simulated RCTs).  
 
When the baseline p-values from RCTs in which concerns about fraudulent data have been 
raised can only be calculated from reported rounded summary statistics, it is still possible to 
compare their distribution with the expected distribution. Visually, the distribution of 
baseline p-values and the AUC-CDF can be compared to the relevant panels in Figure 7 and 
Appendix Figure A.7, or with distributions empirically generated from simulations using the 
reported data. The distribution of baseline p-values in two summary datasets known to 
contain at least some fabricated data (see our previouspaper [6]) differ markedly from the 
expected distributions in Figure 7 and Appendix Figure A.7. Secondly, the distribution of 
baseline p-values can be compared with a control dataset of p-values calculated using 
rounded summary statistics from known genuine RCTs. The distribution of p-values obtained 
through bootstrap resampling can then be repeatedly compared in the two datasets using a 
two sample Kolmogorov–Smirnov test [3, 6].  
 
In summary, randomisation methods, non-normality and correlation of baseline variables do 
not have important effects on the distribution of baseline p-values or the AUC-CDF from 
groups of RCTs, although stratified randomisation and minimisation might lead to smaller-
than-expected proportion of p-values <0.10. In contrast, calculation of p-values from rounded 
summary statistics produces a non-uniform distribution of p-values. Nevertheless, the 
observed distribution can still be compared to the expected distribution of baseline p-values. 
Therefore, assessing the distribution of p-values from the comparison of baseline variables in 
a group of RCTs about which concerns have been raised can be helpful in identifying highly 
unusual distributions that might support concerns about data integrity and lead to further 
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investigations. The limitations have been discussed previously [6], but in general, the 
technique seems most appropriate to analyse at least a moderate number of baseline 
continuous variables from a body of RCTs. While the results should be interpreted 
cautiously, large differences between observed and expected distributions of baseline p-
values justify further investigation.  
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Figure 1: Distribution of 319 p-values for 30 baseline variables in 13 randomised 
controlled trials. Panel A shows the distribution of p-values by decile for all 319 variables, 
and Panel B the distribution of p-values by decile with 95% confidence intervals from 100 re-
randomisations of the original trial data  (n=319 variables, 100 randomisations, thus 31,900 
p-values). The dotted line is the expected uniform proportion of 0.10 in Panels A and B. 
Panel C shows the cumulative distribution function (CDF) of the baseline 319 p-values (solid 
line) with the CDF of the expected uniform distribution (dotted line). ∆ AUC (uniform) is the 
difference in area under the curve (AUC) of the CDF from the AUC of the uniform 
distribution CDF, with the confidence intervals (CI) determined from the AUCs of the CDFs 
from the dataset of 100 original trial re-randomisations.   
 
Figure 2: Effect of randomisation method on baseline p-value distribution.  
Distribution of 319 p-values for all 30 variables from all 13 randomised controlled trials in 
100 simulated randomisations using eight different methods. Panel A simple randomisation. 
Panel B one block per treatment group. Panel C permuted randomisation using fixed blocks 
(4 for 2-arm or 4-arm trials, 3 for 3-arm trials). Panel D variable blocks between 4 and 20 for 
2-arm or 4-arm trials, and 3 and 18 for 3-arm trials. Panel E stratified by median age, weight 
and lumbar spine bone density with one group per stratum. Panel F stratified with fixed block 
sizes of 4 or 3 respectively. Panel G minimisation algorithm for age, weight and lumbar spine 
bone density. Panel H weighted minimisation (20% chance of simple randomisation, 80% 
chance of minimisation algorithm). The dotted line is the expected uniform proportion of 
0.10. ∆ AUC (uniform) is the difference in area under the curve (AUC) of the cumulative 
distribution function (CDF) from the AUC of the uniform distribution CDF. 
 
Figure 3: Effect of normality of distribution on baseline p-value distribution.  
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Panel A shows the 319 p-values by decile for all 30 variables from all 13 randomised 
controlled trials (RCTs) using non-parametric tests. Panel B, 100 simulations of normally 
distributed variables based on the mean and standard deviation from each of the 13 RCTs for 
all 319 baseline variables. Panels C,D results from baseline variables from the 13 RCTs 
(Figure 1) with P<0.05 (Panel C, n=212) or with P<0.001 (Panel D, n=135) from the 
Shapiro-Wilk test. The dotted line is the expected uniform proportion of 0.10. ∆ AUC 
(uniform) is the difference in area under the curve (AUC) of the cumulative distribution 
function (CDF) from the AUC of the uniform distribution CDF, with the confidence intervals 
(CI) determined from the AUCs of the CDFs from a dataset of 100 re-randomisations using 
the original trial randomisation method (Figure 1) in Panels A,C,D, and from the raw data in 
Panel B.   
 
Figure 4: Distribution of pairwise correlations between baseline values in 13 
randomised controlled trials (RCTs) and in the simulated normal dataset. 
The left panel shows the results from the 13 RCTs and the right panel from the simulated 
normal dataset in which 100 normally distributed variables were simulated for each baseline 
variable based on the mean and standard deviation for each variable from each RCT. The bars 
show the proportion and the line the cumulative proportion. 
 
Figure 5: the effect of increasing correlation of baseline variables on the distribution of 
p-values. 
The left panels show the distribution of p-values by decile and the right panels the 
distribution of correlation statistics in 100 simulations of five variables (age, height, weight, 
lumbar spine bone density and serum creatinine) based on the mean, standard deviation and 
covariance matrix from each randomised controlled trial. Panel A uses the covariance matrix 
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from each trial, while in Panels B-D, the pairwise correlations are increased by 0.1, 0.3, and 
0.5 respectively. The bars show the proportion, the line the cumulative proportion, and the 
dotted line the uniform distribution proportion of 0.10. ∆ AUC (uniform) is the difference in 
area under the curve (AUC) of the cumulative distribution function (CDF) from the AUC of 
the uniform distribution CDF.  
 
Figure 6: the effect of clustering and increasing correlation of baseline variables on the 
distribution of p-values. 
The panels show the distribution of p-values by decile in 100 simulations for four variables 
(height, weight, lumbar spine bone density and serum creatinine) based on the mean, standard 
deviation and covariance matrix from each randomised controlled trial (RCT). The left panels 
are restricted to simulations with P<0.10 for the between-groups comparison for age; the 
right panels are restricted to simulations with P>0.90 for age. Panel A uses the covariance 
matrix from each RCT, while in Panels B-D, the pairwise correlations are increased by 
0.1,0.3, and 0.5 respectively. The bars show the proportion and the dotted line the uniform 
distribution proportion of 0.10. ∆ AUC (uniform) is the difference in area under the curve 
(AUC) of the cumulative distribution function (CDF) from the AUC of the uniform 
distribution CDF, with the confidence intervals (CI) calculated using bootstrap resampling. 
 
Figure 7: the effect of rounding on the distribution of baseline p-values calculated from 
summary statistics. 
The panels show the distribution of p-values by decile calculated from rounded summary 
statistics of all 319 baseline variables in 100 simulated randomisations (with individuals 
randomised in one block per treatment group) of 13 randomised controlled trials (RCTs). 
Panel A, variables rounded to a common level (Table 2); Panel B, variables rounded to a 
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more extreme level (Table 2); Panels C-D, common (C) or extreme (D) rounding in two arm 
RCTs; Panels E-F, common (E) or extreme rounding (F) in three or four arm RCTs; Panels 
G-H simulated p-values from common (G) or extreme (H) rounding- see text for description. 
The dotted line is the uniform distribution proportion of 0.10. ∆ AUC (uniform) is the 
difference in area under the curve (AUC) of the cumulative distribution function (CDF) from 
the AUC of the uniform distribution CDF.  
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What is new? 
• Non-normal distribution of baseline continuous variables, eight common 
randomisation methods, and correlation of baseline variables did not have important effects 
on baseline p-value distribution 
• However, the distribution of p-values calculated from rounded summary statistics is 
not uniform although the expected distribution can be empirically generated. 
• Concerns that correlation and non-normality of baseline variables or randomisation 
methods would impact on baseline p-value distribution in genuine RCTs do not appear to be 
justified. 
• Distribution of baseline p-values calculated from rounded summary statistics should 
be compared to empirically generated distributions not the uniform distribution. 
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